GlaxoSmithKline PLC (NYSE:GSK) Position Maintained by Bartlett & Co. LLC

Bartlett & Co. LLC held its position in GlaxoSmithKline PLC (NYSE:GSK) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,008 shares of the pharmaceutical company’s stock at the end of the second quarter. Bartlett & Co. LLC’s holdings in GlaxoSmithKline PLC were worth $216,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the stock. 10 15 Associates Inc. boosted its position in GlaxoSmithKline PLC by 6.4% in the first quarter. 10 15 Associates Inc. now owns 237,716 shares of the pharmaceutical company’s stock valued at $10,022,000 after buying an additional 14,247 shares in the last quarter. Lincluden Management Ltd. boosted its position in GlaxoSmithKline PLC by 1.7% in the first quarter. Lincluden Management Ltd. now owns 120,845 shares of the pharmaceutical company’s stock valued at $5,095,000 after buying an additional 1,990 shares in the last quarter. Anchor Capital Advisors LLC boosted its position in GlaxoSmithKline PLC by 9.6% in the first quarter. Anchor Capital Advisors LLC now owns 613,324 shares of the pharmaceutical company’s stock valued at $25,858,000 after buying an additional 53,894 shares in the last quarter. BlueCrest Capital Management Ltd boosted its position in GlaxoSmithKline PLC by 293.5% in the first quarter. BlueCrest Capital Management Ltd now owns 51,157 shares of the pharmaceutical company’s stock valued at $2,157,000 after buying an additional 38,157 shares in the last quarter. Finally, Roundview Capital LLC boosted its position in GlaxoSmithKline PLC by 157.4% in the first quarter. Roundview Capital LLC now owns 24,529 shares of the pharmaceutical company’s stock valued at $1,034,000 after buying an additional 15,000 shares in the last quarter. 8.96% of the stock is owned by institutional investors and hedge funds.

GlaxoSmithKline PLC (NYSE GSK) traded down 0.28% during midday trading on Friday, hitting $38.79. The stock had a trading volume of 2,329,225 shares. GlaxoSmithKline PLC has a 52 week low of $37.20 and a 52 week high of $44.59. The company has a 50-day moving average price of $41.84 and a 200-day moving average price of $41.84. The stock has a market cap of $94.80 billion, a P/E ratio of 37.51 and a beta of 1.03.

GlaxoSmithKline PLC (NYSE:GSK) last posted its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.02. The company had revenue of $9.36 billion during the quarter, compared to the consensus estimate of $9.52 billion. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. Equities analysts expect that GlaxoSmithKline PLC will post $2.85 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be issued a dividend of $0.491 per share. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date is Wednesday, August 9th. This represents a $1.96 dividend on an annualized basis and a yield of 5.06%. GlaxoSmithKline PLC’s dividend payout ratio is 197.00%.

ILLEGAL ACTIVITY NOTICE: “GlaxoSmithKline PLC (NYSE:GSK) Position Maintained by Bartlett & Co. LLC” was first published by BNB Daily and is owned by of BNB Daily. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.baseball-news-blog.com/2017/08/13/glaxosmithkline-plc-nysegsk-position-maintained-by-bartlett-co-llc-updated-updated-updated.html.

Several equities analysts recently weighed in on GSK shares. Zacks Investment Research cut shares of GlaxoSmithKline PLC from a “hold” rating to a “sell” rating in a research note on Monday, April 17th. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, July 13th. Berenberg Bank raised shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research report on Friday, May 26th. TheStreet raised shares of GlaxoSmithKline PLC from a “c” rating to a “b” rating in a research report on Friday, May 19th. Finally, Citigroup Inc. reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, July 27th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $44.67.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply